SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Taus upcoming oncology milestones are driving attention, particularly the completed IMPACT pancreatic-cancer trial enrollment and expected data, alongside further REGAIN glioblastoma updates. Traders are broadly optimistic about the expanding pipeline, while some emphasize that larger datasets are still needed to validate the early results.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys quarterly results, particularly resilient parks performance and improving streaming profitability, have reinforced bullish sentiment and prompted analyst upgrades. Traders remain divided, with some seeing a turnaround while others point to the stocks long stretch of weak, range-bound performance.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is pulling back after a strong run as traders position ahead of earnings, with some wary of recent SaaS-sector weakness and the stocks valuation. Others remain bullish on growth and AI-driven commerce, while security concerns appear in some bearish posts but are not the dominant discussion.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Attention centers on Candels planned Q4 BLA submission for CAN-2409 in localized prostate cancer and upcoming SITC pipeline data. Bulls see the clinical and regulatory milestones as potential catalysts, while skeptics point to the steep decline, CEO share sales, limited transparency, possible dilution and uncertainty about filing timing; some also blame broader biotech weakness and thin trading.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias early third-quarter report and raised full-year revenue guidance are driving attention, with continued LUPKYNIS sales growth supporting the results. Traders are split between viewing the report as solid execution and frustration that the shares fell despite it, compounded by confusion over whether management held an earnings call.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys shares are drawing attention after a sharp post-earnings rally despite revenue and EPS misses; traders are focusing on premium subscriber growth, stronger gross margin, and an upbeat fourth-quarter profit outlook. The move has surprised some investors, who question why the stock rose on a mixed report, while bulls see the guidance and improving ad revenue as the more important signals.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

ALAB is drawing attention amid a sharp pullback alongside other AI and semiconductor stocks, with traders citing stretched valuations, broad market pressure, and uncertainty ahead of earnings. The community is split between buyers treating the decline as an opportunity and bears warning that the stock remains overvalued and could fall further.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs large equity and warrant offering, alongside its Elisity acquisition, has put dilution and capital allocation at the center of the discussion as shares have sold off. Bulls see the financing and acquisitions as building a broader quantum platform, while critics question shareholder costs and execution; a Google quantum breakthrough has also lifted sector optimism, though traders disagree on whether that can overcome IONQ-specific concerns.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could weaken in 2027 has sparked concerns about pricing and CorMedixs largest revenue driver, contributing to a sharp selloff. Traders are divided over the impact: some see a serious commercial risk, while others argue DaVitas outlook is preliminary and point to CMS reimbursement estimates as a reason the reaction may be excessive.

NEAR Protocol (NEAR) is a cryptocurrency launched in 2020. NEAR Protocol has a current supply of 1,310,395,414. The last known price of NEAR Protocol is 4.30157975 USD and is up 6.10 over the last 24 hours. It is currently trading on 688 active market(s) with $1,245,620,491.67 traded over the last 24 hours. More information can be found at https://near.org/.

Near

Traders are watching a governance vote that could make NEAR less inflationary, with some viewing the tokenomics change as a potential catalyst. Sentiment is split: dip-buyers are accumulating, while cautious traders point to Bitcoin-linked weakness and liquidation risk.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Enlivex Ltd. (ENLV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Enlivex Ltd. (ENLV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why

Enlivex Ltd. (ENLV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Enlivex Ltd. (ENLV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Enlivex Therapeutics (NASDAQ:ENLV) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded shares of Enlivex Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...

HC Wainwright Issues Pessimistic Outlook for ENLV Earnings

Enlivex Therapeutics Ltd. (NASDAQ:ENLV - Free Report) - Equities research analysts at HC Wainwright reduced their Q1 2026 earnings estimates for Enlivex Therapeutics in a research note issued to...

Research Analysts Set Expectations for ENLV Q1 Earnings

Enlivex Therapeutics Ltd. (NASDAQ:ENLV - Free Report) - Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Enlivex Therapeutics in a report released on Tuesday, April 7th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.02) per share...

HC Wainwright Forecasts Strong Price Appreciation for Enlivex Therapeutics (NASDAQ:ENLV) Stock

HC Wainwright boosted their target price on shares of Enlivex Therapeutics from $13.00 to $20.00 and gave the company a "buy" rating in a research report on Tuesday...

Enlivex Therapeutics (NASDAQ:ENLV) Stock Rating Lowered by Wall Street Zen

Wall Street Zen cut shares of Enlivex Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...

Enlivex Therapeutics Q4 Earnings Call Highlights

Enlivex Therapeutics (NASDAQ:ENLV) executives used the company's fourth-quarter and full-year 2025 earnings call to outline what they described as a dual-engine strategy that combines clinical-stage...

Enlivex Therapeutics (NASDAQ:ENLV) Releases Earnings Results, Beats Estimates By $12.88 EPS

Enlivex Therapeutics (NASDAQ:ENLV - Get Free Report) released its quarterly earnings data on Wednesday. The company reported $12.85 earnings per share for the quarter, beating analysts' consensus...

Enlivex Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.

Enlivex Ltd.

ENLV Stock Surges After Pivot To Crypto-Backed Treasury, Names Former Italian PM To Board 

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Private investment in public equity (PIPE) raised $212 million through 212 million shares at $1 each.</li><li>Former Italian Prime Minister Matteo Renzi will join Enlivex’s board following the PIPE deal.</li><li>Enlivex aims to capture the growing prediction market sector, targeting competition with Polymarket and Kalshi.</li></ul>Shares of biotech company Enlivex Therapeutics (ENLV) jumped in pre-market trade on Monday after the company announced it would now be pivoting towards a crypto-backed treasury, with Rain Coin as its official token.&nbsp;The company also said that former Italian Prime Minister Matteo Renzi will be appointed to its board of directors.&nbsp;<a href="https://stocktwits.com/symbol/ENLV">ENLV’s stock</a> gained more than 70% in pre-market trade. On Stocktwits, retail sentiment around the company jumped to ‘extremely bullish’ from ‘neutral’ over the past day. Chatter increased to ‘extremely high’ from ‘high’ levels.&nbsp;Meanwhile,&nbsp;<a href="https://stocktwits.com/coins/rain-coin">RAIN’s price</a> nearly doubled in the last 24 hours. Retail sentiment around the token improved to ‘bullish’ from ‘neutral territory over the past day, accompanied by chatter at ‘high’ levels.&nbsp;<h2 class="st-heading-2">PIPE Deal To Fund RAIN Strategy</h2>Enlivex announced a private investment in public equity (PIPE) deal to raise $212 million by selling 212 million shares at $1 each, roughly 11.5% above last Friday’s closing price. The investment will be funded in both U.S. dollars and Tether’s USDT (USDT). Net proceeds are earmarked to implement “the first RAIN prediction markets token treasury strategy.”&nbsp;The company said it would also maintain focus on its core operations, including the late-stage clinical development of Allocetra, a therapy for osteoarthritis.<h2 class="st-heading-2">Targeting The Prediction Market Sector</h2>RAIN is a fully decentralized prediction and options protocol built on the Arbitrum network. With the protocol, Enlivex aims to capture the same growing market as firms like Polymarket and Kalshi, which have attracted billions in institutional investment.In October 2025, Polymarket secured a $2 billion investment from Intercontinental Exchange Inc. (ICE), the parent company of the New York Stock Exchange, which valued the company at around $8 billion. Meanwhile, Kalshi recently closed a $1 billion funding round in November 2025, which lifted its valuation to $11 billion.The PIPE transaction is expected to close on or before Tuesday.Read also:&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://cms.stocktwits.com/admin/content-manager/collection-types/api::article.article/16925">Bitcoin Holds $86,000 With Crypto Market Back Above $3 Trillion – XRP, Doge Gain Ahead Of Grayscale’s New ETF Launches</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Financial market volatility on digital interface with fluctuating trading data real-time stock market analysis and investment trends. (Stock picture/Getty Images)

RAIN token price nearly doubled, with retail sentiment on Stocktwits trending ‘bullish’ and chatter at ‘high’ levels.

Enlivex Therapeutics Ltd

Rain Coin

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.78
Prev Close	$2.54
Open	$2.47
Dividend Yield	0.00%
50-Day Moving Average	$10.56
Beta	0.76
Avg. Volume	28,524.90
PE Ratio	0.00

52-Week High	$434.40
52-Week Low	$1.73
Market Capitalization	$2.73M
EPS (Annual)	$6,114.09
Price to Book	0.00
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

ENLV Fundamentals